About
With over 20 years of international leadership experience across the healthcare, biotechnology, and pharmaceutical industries, I bring a unique blend of scientific rigor, strategic foresight, and operational execution. I have held senior positions in global organizations such as GSK, where I led disruptive R&D innovation programs, built and managed multidisciplinary teams, and initiated strategic alliances with global tech and deep-tech leaders like Microsoft and IMEC.
What sets me apart as an advisor or board member is my ability to translate cutting-edge science into actionable corporate strategy and to support organizations at the intersection of innovation, market need, and value creation. My background combines academic excellence (PhD, MBA, executive programs at MIT, Vlerick, and HEC) with practical industry leadership, enabling me to offer both high-level strategic vision and pragmatic guidance on execution. I also bring experience in corporate governance, strategic partnerships, early-stage venture building, and technology portfolio management.
Companies that would benefit most from my expertise are those navigating complex innovation environments—particularly early-stage or growth-phase biotech, medtech, or digital health companies aiming to scale transformative technologies. Whether advising on R&D strategy, pipeline design, go-to-market planning, or partnership development, I help organizations unlock value at critical inflection points and prepare for sustainable growth.
What sets me apart as an advisor or board member is my ability to translate cutting-edge science into actionable corporate strategy and to support organizations at the intersection of innovation, market need, and value creation. My background combines academic excellence (PhD, MBA, executive programs at MIT, Vlerick, and HEC) with practical industry leadership, enabling me to offer both high-level strategic vision and pragmatic guidance on execution. I also bring experience in corporate governance, strategic partnerships, early-stage venture building, and technology portfolio management.
Companies that would benefit most from my expertise are those navigating complex innovation environments—particularly early-stage or growth-phase biotech, medtech, or digital health companies aiming to scale transformative technologies. Whether advising on R&D strategy, pipeline design, go-to-market planning, or partnership development, I help organizations unlock value at critical inflection points and prepare for sustainable growth.
Frederic Sallmann is an advisor and board member based in Belgium, specialising in Biotechnology. They speak English and French. They are open to advisory board and board director opportunities and are available for introductions through Boardio.
Boardio matches companies with experienced advisors and board members across 120 countries — this is one of 12k+ profiles in the network.
Looking for advisors?
Browse now
Interested in becoming an advisor?
See opportunities
